Obesity and comorbid binge eating are serious health problems for more than 40% of adults across the US.7Health complications due to obesity comprise more than 20% of the nation's healthcare budget, and thehealthcare costs of individuals with binge eating are $18,152 higher than in obese peers without binge eating.13The prevalence of binge eating and the substantial burden of healthcare costs highlight the need for treatmentsthat eliminate binge eating and produce weight loss. Despite this, there is a paucity of interventions thataddress these comorbid conditions. In this Phase 1 project, we seek to build a digital therapeutic (calledOTX-401) that will be ready for testing in a large, multi-site, well-powered clinical trial during Phase 2. Positiveresults will be the critical initial step to facilitating the widespread implementation and commercialization of thedigital therapeutic to enhance access to highly personalized obesity and binge eating intervention.
Public Health Relevance Statement: PROJECT NARRATIVE
Approximately 80 million adults in the US over the age of 20 have obesity. Among obese adults who seek
treatment, more than 25% engage in binge eating; this comorbidity has more severe health outcomes and is
more costly to treat than obesity alone. Oui Therapeutics seeks to partner with leading researchers in the field
of eating disorders to develop a novel self-guided digital intervention product (called OTX-401) for the
treatment of obesity combined with binge eating.
Project Terms: <21+ years old>
